Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease

Journal of Clinical Neurology (Korea)

Volumn 7, Issue 3, 2011, Pages 137-142

  Han, Hyun Jeong ^a   Lee, Jeong Ju ^b   Park, Sun A ^c   Park, Hyun Young ^d   Kim, Jeong Eun ^e   Shim, Young Soo ^f   Shim, Dong Seok ^f   Kim, Eun Joo ^g   Yoon, Soo Jin ^h   Choi, Seong Hye ⁱ  

^a Hanyang Medical Center   (South Korea)

^b Sejong General Hospital   (South Korea)

^c Soonchunhyang University College of Medicine   (South Korea)

^d Wonkwang University   (South Korea)

^e Ewha Womans University School of Medicine   (South Korea)

^f The Catholic University of Korea   (South Korea)

^g Pusan National University Hospital   (South Korea)

^h Eulji University   (South Korea)

ⁱ Inha University School of Medicine   (South Korea)

Author keywords

Alzheimer's disease; Efficacy; Rivastigmine transdermal patch; Safety; Zcholinesterase inhibitors

Indexed keywords

EID: 80053458964     PISSN: 17386586     EISSN: 20055013     Source Type: Journal    
DOI: 10.3988/jcn.2011.7.3.137     Document Type: Article

References (22)

1. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-1166.
2. Ritchie CW, Ames D, Clayton T, Lai R. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 2004;12:358-369.
3. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005;331: 321-327.
4. Imbimbo BP. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 2001;15:375-390.
5. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 2002:45-63.
6. Small G, Dubois B. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin 2007;23:2705-2713.
7. Winblad B, Machado JC. Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease. Expert Opin Drug Deliv 2008; 5:1377-1386.
8. Cummings J, Lefèvre G, Small G, Appel-Dingemanse S. Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007;69:S10-S13.
9. Blesa R, Ballard C, Orgogozo JM, Lane R, Thomas SK. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology 2007;69:S23-S28.
10. Ellis JM. Cholinesterase inhibitors in the treatment of dementia. J Am Osteopath Assoc 2005;105:145-158.
11. Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Curr Med Res Opin 2003; 19:707-714.
12. Bullock R, Connolly C. Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it? Int J Geriatr Psychiatry 2002;17:288-289.
13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984; 34:939-944.
14. Kang Y, Na DL, Hahn S. A validity study on the Korean mini-mental state examination (K-MMSE) in dementia patients. J Korean Neurol Assoc 1997;15:300-308.
15. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-1153.
16. Guy W. Early Clinical Drug Evaluation Unit (ECDEU) assessment manual for psychopharmacology. Bethesda, MD: National Institute of Mental Health, 1976.
17. Kang SJ, Choi SH, Lee BH, Kwon JC, Na DL, Han SH, et al. The reliability and validity of the Korean instrumental activities of daily living (K-IADL). J Korean Neurol Assoc 2002;20:8-14.
18. Choi SH, Na DL, Lee BH, Hahm DS, Jeong JH, Yoon SJ, et al. Estimating the validity of the Korean version of expanded clinical dementia rating (CDR) scale. J Korean Neurol Assoc 2001;19:585-591.
19. Auriacombe S, Pere JJ, Loria-Kanza Y, Vellas B. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002;18:129-138.
20. Sadowsky CH, Farlow MR, Atkinson L, Steadman J, Koumaras B, Chen M, et al. Switching from donepezil to rivastigmine is well tolerated: results of an open-label safety and tolerability study. Prim Care Companion J Clin Psychiatry 2005;7:43-48.
21. Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere JJ, Bourdeix I. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract 2006;60:110-118.
22. Grossberg G, Sadowsky C, Fröstl H, Frölich L, Nagel J, Tekin S, et al. Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension. Alzheimer Dis Assoc Disord 2009;23:158-164.